NL-OMON38707尚未招募不适用
Therapeutic Drug Monitoring of BRAF- and MEK-inhibitors in a *Real Life* Cohort of Melanoma Patients - N12VDT: The BRAF- and MEK-inhibitor cohort study
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 120 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •All eligible patients (starting or already using) using vemurafenib, dabrafenib and/or trametinib for treatment of cancer. (Patients that are in a (sponsored) clinical trial that receive dabrafenib and/or trametinib will not be included, unless allowed by the other protocol);
- •Age 18 years or >18 years;
- •Patients from whom it is possible to collect blood samples;
- •Patients that are able and willing to undergo a finger prick for dried blood spot sampling;
- •Patients that are able and willing to give written informed consent;
排除标准
- •The study objective is to monitor vemurafenib, dabrafenib and trametinib therapy in a *real life* cohort of patients. Therefore no strict exclusion criteria will be used.
研究者
相似试验
已完成
不适用
Therapeutic Drug Monitoring of BRAF-mutated Advanced MelanomaMelanoma (Skin)NCT03416933Institut de Cancérologie de Lorraine35
进行中（未招募）
早期 1 期
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaMelanoma (Skin)Skin MelanomaSkin CarcinomaSkin CancerNCT03543969H. Lee Moffitt Cancer Center and Research Institute14
已完成
不适用
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic MelanomaMalignant MelanomaNCT02143999Hoffmann-La Roche403
进行中（未招募）
2 期
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaBRAF V600E Mutation PresentPapillary CraniopharyngiomaNCT03224767Alliance for Clinical Trials in Oncology24
尚未招募
不适用
Observational Study of BRAF Inhibitor Combination Therapy for BRAF mutant Metastatic Colorectal Cancer including Biomarker Research: BEETS trial(JACCRO CC-18)Colorectal CancerJPRN-UMIN000045530JACCRO200